Management to Host Webcast today at 8:30 am ET to discuss Results and Provide Business Update
OMER, Israel, Aug. 31, 2026 /PRNewswire/ -- Pulsenmore Ltd. $(PLSM)$ (TASE: PLSM), a leading innovator in remote maternal-fetal healthcare and home ultrasound solutions, presents the key operational, commercial, regulatory, and technological achievements as well as financial updates for the six month period ended June 30, 2026.
During the first half of 2026, Pulsenmore advanced its commercialization efforts in the United States following FDA marketing authorization for its home ultrasound platform, while continuing to advance product development, regulatory approvals, prepare for manufacturing and pursue strategic collaborations.
H1 2026 Highlights
Commercial & Business Development
-- The Company officially launched its U.S. commercial activities following
FDA market authorization and showcased its platform at the Society for
Maternal-Fetal Medicine (SMFM) Pregnancy Meeting in Las Vegas in February
2026.
-- The Company signed its first U.S. commercial agreements with:
-- The Center for Fetal Maternal Ultrasound (CFFM) in Los Angeles,
California
-- TLC Perinatal Care in Silver Spring, Maryland
-- The Company completed its first provider onboarding in the United States
at the end of January 2026.
-- The Company recorded its first U.S. home ultrasound patient scan during
February 2026.
-- Pulsenmore's U.S. e-commerce platform officially opened for online orders
in April 2026.
-- The Company expanded discussions with digital health and maternal-care
organizations regarding potential collaborations intended to support
broader access to virtual obstetric care.
-- In June 2026, the Company announced a strategic partnership with Ouma
Health to expand access to remote prenatal care across the U.S. The
collaboration aims to deliver transformative care for the most
underserved patients including those living in maternity deserts and
underserved communities and establish insights and experience to support
future expansion opportunities with healthcare systems, maternity care
providers, and payer organizations seeking innovative approaches for
maternal health delivery.
-- In August 2026, the Company announced that its home ultrasound technology
will be integrated at Lis Maternity and Women's Hospital at Ichilov,
expanding the ability to incorporate at-home ultrasound scans as part of
pregnancy monitoring.
Strategic Partnerships & Healthcare Expansion
-- Pulsenmore signed an addendum to its agreement with Clalit Health
Services, regarding its Pulsenmore FC (follicles monitoring) product,
strengthening its collaboration in Israel.
Product Development & Technology
-- The Company supported FDA and AMAR submissions for the ES Tera product
line (compatible for both iOS and Android devices). The Company received
applicable regulatory clearances or authorizations for the ES Tera
product line from the FDA and Israel's Ministry of Health Medical Device
Division, as applicable.
-- Initial ES Tera production lots and first shipments to the U.S. market
were completed
-- After the period ended June 30, 2026, in July 2026, the Company announced
that it has been selected to participate in Israel's Healthcare AI
Regulatory Sandbox Program, established by the Israel Innovation
Authority and the Ministry of Health. As part of the program, the Company
will lead a NIS 3 million (approximately $1 million) project in which the
grant approved amounted to NIS 1.2 million (approximately $0.4 million).
In August 2026, the Company announced that it received a second AI grant,
after the Israel Innovation Authority approved NIS 3.8 million
(approximately $1.27 Million) for the SmartScan AI Program. The second
grant brings the total AI grants approved for the Company in the past
months to NIS 5 million (approximately $1.67 million), supporting two
programs with a combined scope of NIS 9.3 million approximately $3.12
million.
Manufacturing & Operations
-- Pulsenmore sold approximately 4,265 devices during the first half of 2026
-- Pulsenmore progressed planning for new production facilities and
infrastructure expansion
-- The Company continued development of its proprietary automated ultrasound
transducer production line, with plans to establish automated
manufacturing operations in Israel beginning in 2027.
Intellectual Property
Pulsenmore strengthened its intellectual property portfolio with multiple newly granted patents during H1 2026, including patents related to:
-- Ultrasound imaging systems for non-skilled users -- Systems for acquiring ultrasound images -- Wearable ultrasonic devices
Regulatory Achievements
Key regulatory milestones achieved during H1 2026 included:
-- U.S. clearance expansion for the Pulsenmore ES Tera device
-- Submission of a Q-Sub application for potential expansion of Pulsenmore
ES indications in the U.S
Private Placement with a Single Healthcare Focused Institutional Investor
In June 2026, the Company entered into a securities purchase agreement with a healthcare-focused institutional investor, for the purchase and sale of 1,562,500 pre-funded warrants and ordinary warrants to purchase up to 1,562,500 ordinary shares in a private placement at a combined purchase price of $4.7999 per pre-funded warrant and accompanying ordinary warrant), representing a premium to the then Nasdaq Minimum Price under Nasdaq rules.
The gross proceeds from the offering were NIS 22.5 million (approximately $7.5 million), before deducting placement agent commissions and other offering expenses.
Management Commentary
"The first half of 2026 marked a transformative period for Pulsenmore as we initiated commercial operations in the United States following FDA authorization and achieved multiple strategic milestones across commercialization, regulation, manufacturing, and innovation," said Dr. Elazar Sonnenschein, Chief Executive Officer of Pulsenmore Ltd. "As we move into the second half of the year, our focus is on scaling the commercial base and converting the early stages of this year to actual revenues. We believe our achievements to date position Pulsenmore for continued growth as we expand access to remote maternal-fetal healthcare worldwide."
Financial Results for the period ended June 30, 2026
-- Revenues for the six months ended June 30, 2026, amounted to NIS 6.1
million (approximately $2 million), representing an increase of NIS 2.1
million (approximately $0.7 million), or 53%, compared to NIS 4 million
(approximately $1.3 million) for the six months ended June 30, 2025. The
increase in revenues from 2025 to 2026 resulted primarily from a higher
volume of Pulsenmore ES units sold to our main customer, Clalit, fueled
by the Company's enhanced marketing efforts, and also from revenue
recognition of 300 Pulsenmore FC units in 2026.
-- Gross profit for the six months ended June 30, 2026, amounted to NIS 2.2
million (approximately $0.7 million), representing an increase of NIS 0.7
million (approximately $0.2 million) or 53%, compared to NIS 1.5 million
(approximately $0.5 million) for the six months ended June 30, 2025. The
gross profit resulted primarily from a higher volume of Pulsenmore ES
units sold, and also from revenue recognition of 300 Pulsenmore FC units
in 2026.
-- Operating expenses for the six months ended June 30, 2026, amounted to
NIS 23 million (approximately $7.7 million), representing an increase of
NIS 0.9 million (approximately $0.3 million) or 4%, compared to NIS 22.1
million (approximately $7.4 million) for the six months ended June 30,
2025. The increase in operating expenses was primarily attributable to
the Company's ongoing commercialization activities, product development
efforts, and advertising expenses.
-- Operating loss amounted to NIS 20.8 million (approximately $7 million)
for the six months ended June 30, 2026, compared to operating loss of NIS
20.6 million (approximately $6.9 million) for the six months ended June
30, 2025, representing an increase of NIS 0.2 million (approximately $0.1
million), or 1%.
-- Net financial expenses for the six months ended June 30, 2026, amounted
to NIS 14.3 million (approximately $4.8 million), representing an
increase of NIS 11.8 million (approximately $4 million), or 472%,
compared to NIS 2.5 million (approximately $0.8 million) for the six
months ended June 30, 2025. The increase was driven primarily by the
private placement completed during the period, which resulted in the
recognition of the excess of initial fair value of pre-funded warrants
over transaction proceeds.
-- Total comprehensive loss for the six months ended June 30, 2026, amounted
to NIS 35 million (approximately $11.8 million), compared to total
comprehensive loss of NIS 23.2 million (approximately $7.7 million) for
the six months ended June 30, 2025, representing an increase of NIS 11.8
million (approximately $4.1 million), or 51%.
-- As of June 30, 2026, the Company had cash, cash equivalents, and
short-term bank deposits of NIS 70 million (approximately $23.4 million)
Webcast Details
Pulsenmore will host a webcast to review the results today on August 31 at 8:30am Eastern Time / 3:30pm Israel Time.
Webcast: https://teams.microsoft.com/meet/35050418577919?p=r5gfAIMDL65KJ8zKj3
A replay of the webcast will be available following the call on the Company's Investor Relations website at: https://pulsenmore.com/investor_relations
About Pulsenmore Ltd.
Pulsenmore Ltd. (Nasdaq/TASE: PLSM) is a healthcare technology company focused on transforming maternal-fetal healthcare through remote ultrasound and telemedicine solutions. The Company develops self-use and remote clinical ultrasound systems designed to improve accessibility, continuity of care, and patient engagement in pregnancy monitoring.
For more information, visit: www.pulsenmore.com
Forward-Looking Statements
This press release contains forward-looking statements. In particular, statements using words such as "may," "seek," "will," "consider," "likely," "assume," "estimate," "expect," "anticipate," "intend," "believe," "contemplate," "do not believe," "aim," "goal," "due," "predict," "plan," "project," "continue," "potential," "positioned," "guidance," "objective," "outlook," "trends," "future," "could," "would, " "should," "target," "on track" or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. Such forward-looking statements include, but are not limited to, statements relating to Pulsenmore's continued commercial momentum, potential expansion in the United States, opportunities, expected benefits and outcomes of collaborations and strategic partnerships, and planned manufacturing expansion and automated manufacturing operations. Forward-looking statements reflect Pulsenmore's current views, plans, or expectations with respect to future events or financial performance. They are inherently subject to significant business, economic, competitive, and other risks, uncertainties, and contingencies. Forward-looking statements are based on Pulsenmore's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, but not limited to, the following: the Company's lack of operating history; the Company's current and future capital requirements and the Company's belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company's ability to manufacture, market and sell its products and to generate revenues; the Company's ability to maintain its relationships with key partners and grow relationships with new partners; the Company's ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company's ability to launch and penetrate markets in new locations and new market segments; the Company's ability to retain key executive members and hire additional personnel; the Company's ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company's ability to achieve greater regulatory compliance needed in existing and new markets; the Company's ability to achieve key performance milestones in its planned operational testing; the Company's ability to establish adequate sales, marketing and distribution channels; security, political and economic instability in the Middle East that could harm its business; and acceptance of the Company's business model by investors. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the SEC, including, but not limited to, the risks, uncertainties and other factors included in the Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2025 and in subsequent filings with the SEC. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as otherwise required by law.
The financial information is presented in NIS millions (unless otherwise stated) and the figures presented are rounded accordingly. The convenience translations of the New Israeli Shekel (NIS) figures into US Dollars were made at the rate of exchange prevailing on June 30, 2026: US $1.00 equals NIS 2.978. The translations were made purely for the convenience of the reader.
Investor Contact
Miri Segal-Scharia MS-IR LLC
msegal@ms-ir.com
PULSENMORE LTD.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION
(UNAUDITED)
Convenience
translation
into
U.S. dollars
(see note 2(b))
----------------
December 31, June 30,
------------- ---------------------------
2025 2026 2026
------------- --------- ----------------
NIS in thousands in thousands
------------------------ ----------------
Assets
CURRENT ASSETS
Cash and cash equivalents 21,604 43,584 14,635
Short-term bank deposits 47,531 26,180 8,791
Restricted deposits 140 - -
Trade receivables 4,144 2,382 800
Other receivables 1,391 1,832 615
Inventory -- current portion 6,593 6,345 2,131
------------ --------- ----------------
Total current assets 81,403 80,323 26,972
------------ --------- ----------------
NON-CURRENT ASSETS
Inventory -- non-current
portion 13,337 13,742 4,615
Right-of-use assets 1,285 752 253
Property and equipment, net 5,822 5,089 1,709
------------ --------- ----------------
Total non-current assets 20,444 19,583 6,577
------------ --------- ----------------
Total assets 101,847 99,906 33,549
============ ========= ================
Liabilities and equity
CURRENT LIABILITIES
Trade payables 1,980 3,463 1,163
Warrants - 33,198 11,148
Other payable and accruals 4,407 4,121 1,384
Contract liabilities 938 81 27
Share-based compensation
liability 276 278 93
Current maturities of
liability for royalties to
the Israel Innovation
Authority 1,705 1,693 569
Current maturities of lease
liabilities 1,023 840 282
------------ --------- ----------------
Total current liabilities 10,329 43,674 14,666
------------ --------- ----------------
NON-CURRENT LIABILITIES
Liability for royalties to
the Israel Innovation
Authority, net of current
maturities 7,886 7,575 2,544
Lease liabilities, net of
current maturities 542 319 107
------------ --------- ----------------
Total non-current liabilities 8,428 7,894 2,651
------------ --------- ----------------
Total liabilities 18,757 51,568 17,317
------------ --------- ----------------
EQUITY
Ordinary shares 2 2 1
Share premium 256,137 256,137 86,009
Capital reserve 10,092 10,412 3,497
Accumulated deficit (183,141) (218,213) (73,275)
------------ --------- ----------------
Total equity 83,090 48,338 16,232
------------ --------- ----------------
Total liabilities and equity 101,847 99,906 33,549
============ ========= ================
PULSENMORE LTD.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS
(UNAUDITED)
Convenience
translation into
U.S. dollars
(see note 2(b))
-----------------
Six months ended June 30,
---------------------------------------------
2025 2026 2026
------------ ------------ -----------------
in thousands
NIS in thousands (except per
(except per share data) share data)
-------------------------- -----------------
Revenues 3,999 6,080 2,042
Cost of revenues 2,542 3,855 1,294
------------ ------------ -----------------
Gross profit 1,457 2,225 748
Research and development
expenses, net 8,029 8,459 2,840
Sales and marketing
expenses 5,966 6,382 2,143
General and administrative
expenses 8,083 8,141 2,734
------------ ------------ -----------------
Operating loss 20,621 20,757 6,969
Financial expenses 4,766 15,962 5,359
Financial income (2,231) (1,647) (553)
------------ ------------ -----------------
Financial expenses, net 2,535 14,315 4,806
Loss before income tax 23,156 35,072 11,775
============ ============ =================
Provision for income tax 1 - -
------------ ------------ -----------------
Net loss and comprehensive
loss 23,157 35,072 11,775
============ ============ =================
Loss per ordinary share --
basic and diluted (*) 3.6 5.39 1.83
============ ============ =================
Weighted average ordinary
shares outstanding 6,429,059 6,502,844 6,502,844
============ ============ =================
(*) Basic loss per share does not include the above-mentioned 1,562,500
pre-funded warrants since they are accounted for as a liability. In
addition, the impact of the pre-funded warrants has not taken in the
diluted weighted average number of ordinary shares calculation as their
effect would have been anti-dilutive.
PULSENMORE LTD.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY
(UNAUDITED)
Ordinary Share Capital Accumulated
shares premium reserve deficit Total
-------------- ------- ------- ----------- --------
NIS in thousands
-------------------------------------------------------
Balance at
January 1,
2025 2 253,205 10,968 (167,288) 96,887
Changes in the
six month
period ended
June 30,
2025:
Net loss and
comprehensive
loss for the
year - - - (23,157) (23,157)
Share-based
compensation - - 506 - 506
Exercise of
options * 471 (199) - 272
Expiration of
options - 280 (280) - -
-------------- ------- ------- ----------- --------
Balance at June
30, 2025 2 253,956 10,995 (190,445) 74,508
Balance at
January 1,
2026 2 256,137 10,092 (183,141) 83,090
Changes in the
six month
period ended
31June 30,
2026:
Net loss and
comprehensive
loss for the
year - - - (35,072) (35,072)
Share-based
compensation - - 320 - 320
Balance at June
30, 2026 2 256,137 10,412 (218,213) 48,338
============== ======= ======= =========== ========
* Less than NIS 1 thousand
PULSENMORE LTD.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY
(UNAUDITED)
Convenience translation into U.S. dollars (see note
2(b))
---------------------------------------------------
in thousands
Ordinary Share Capital Accumulated
shares premium reserve deficit Total
-------- -------- -------- ----------- --------
Balance at
January 1,
2026 1 86,009 3,390 (61,500) 27,900
Changes in the
six month
period ended
June 30,
2026:
Net loss and
comprehensive
loss for the
year - - - (11,775) (11,775)
Share-based
compensation - - 107 - 107
Balance at June
30, 2026 1 86,009 3,497 (73,275) 16,232
======== ======== ======== =========== ========
PULSENMORE LTD.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS
Convenience
translation into
U.S. dollars
(see note 2(b))
-----------------
Six months ended June 30,
----------------------------------------
2025 2026 2026
---------- --------- -----------------
NIS in thousands in thousands
--------------------- -----------------
Net cash used in
operating activities
(see appendix) (15,570) (17,571) (5,900)
--------- --------- -----------------
Cash Flows from
Investing
Activities
Purchase of property
and equipment (97) (134) (45)
Proceeds from
(investment in)
short-term deposits (2,289) 19,231 6,458
Interest received 964 1,291 434
--------- --------- -----------------
Net cash provided by
(used in) investing
activities (1,422) 20,388 6,847
--------- --------- -----------------
Cash Flows from
Financing
Activities
Proceeds from private
placement - 22,507 7,558
Transaction costs
related to private
placement - (1,738) (584)
Exercise of options 4 - -
Payment to the Israel
Innovation
Authority (287) (160) (53)
Receipt of grants
from Israel
Innovation
Authority 1,319 - -
Principal portion of
lease payments (574) (652) (218)
Interest portion of
lease payments (94) (59) (20)
--------- --------- -----------------
Net cash provided by
in financing
activities 368 19,898 6,683
--------- --------- -----------------
Increase (decrease)
in cash and cash
equivalents (16,624) 22,715 7,630
Cash and cash
equivalents at
beginning of the
period 41,170 21,604 7,255
Exchange differences
on cash and cash
equivalents (105) (735) (250)
--------- --------- -----------------
Cash and cash
equivalents at end
of the period 24,441 43,584 14,635
========= ========= =================
PULSENMORE LTD.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS
Convenience
translation into
Appendix to the statements of cash U.S. dollars
flows (see note 2(b))
-----------------
Six months ended June 30,
-------------------------------------
2025 2026 2026
-------- -------- -----------------
NIS in thousands in thousands
------------------ -----------------
Net loss (23,157) (35,072) (11,775)
Adjustments for:
Depreciation and amortization 1,432 1,521 511
Share-based compensation 506 320 107
Financial expenses (income) (15) 12,527 4,207
Exchange differences 3,356 1,627 546
-------- -------- -----------------
5,279 15,995 5,371
-------- -------- -----------------
Changes in operating asset and
liability items:
Decrease in trade receivables 1,240 1,762 592
Increase in other receivables (22) (441) (149)
Increase (decrease) in inventory 1,465 (157) (53)
Increase (decrease) in trade
payables (207) 1,483 498
Decrease in other payables and
accruals (379) (286) (97)
Increase (decrease) in contract
liabilities 193 (857) (288)
Increase in liability of
share-based compensation 18 2 1
-------- -------- -----------------
2,308 1,506 504
-------- -------- -----------------
Net cash used in operating
activities (15,570) (17,571) (5,900)
======== ======== =================
Supplemental information on
non-cash transactions:
Changes in right-of-use asset and
lease liabilities 110 37
======== ======== =================
Changes in share-based compensation
liability (268) - -
======== ======== =================
View original content to download multimedia:https://www.prnewswire.com/news-releases/pulsenmore-ltd-announces-financial-results-and-business-highlights-for-the-first-half-of-2026-302864879.html
SOURCE Pulsenmore Ltd.